Search

Your search keyword '"Shah, Urvi A"' showing total 87 results

Search Constraints

Start Over You searched for: Author "Shah, Urvi A" Remove constraint Author: "Shah, Urvi A" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
87 results on '"Shah, Urvi A"'

Search Results

1. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

2. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

3. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

5. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

7. Whole-genome landscape of adult T-cell leukemia/lymphoma

8. Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy

9. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

10. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma

12. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

13. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies

14. P09-002-23 Assessing Dietary Compliance of a Plant-Based Dietary Intervention in Patients With Precursor Plasma Cell Disorders - The Nutrition Prevention (NUTRIVENTION) Study

15. Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

16. Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

18. A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression

19. A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study

20. A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea

21. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

23. Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

24. Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study

25. Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

26. Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

30. The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

31. Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

32. Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

33. P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma

34. P-484 Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias

35. P-483 A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: the NUTRIVENTION trial

37. P-354 Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology

38. P-166 Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma

39. P-162 Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma

41. P-089 Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma

42. P-039 Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma

43. P-038 Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)

44. P-013 Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

45. P-007 Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/ refractory multiple myeloma

46. OA-19 Comprehensive genomic characterization of response and resistance to daratumumab – based quadruplet induction in newly diagnosed multiple myeloma patients

47. OA-03 Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma

50. A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Catalog

Books, media, physical & digital resources